Weitao Jia, Ph.D.Director, CMC Analytical Development Technical Operations at Ultragenyx
Dr. Weitao Jia is the Director in CMC Analytical Development at Ultragenyx, California. He is currently leading a late-stage BLA project and working on a few early-stage development projects including mRNA-based therapeutics. Dr. Jia was previously working at Roche/Genentech for 9 years and was the CMC characterization/analytical lead as well as the global analytical technology transfer lead of Susvimo® which received FDA’s approval in October 2021. He earned his Ph.D. in Analytical Chemistry and gained extensive CMC development experiences via working on a few BLA projects with successful commercial launches and leading characterization/analytical work for Phase I/III INDs/CTAs.